Wednesday, July 31, 2019

Retinal Vein Occlusion Market is projected to register a CAGR of 11.2% By 2023

Market Highlights
Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein occlusion market offering a huge growth opportunity to the market players. Moreover, the growing number of patients affected with lymphoma and multiple myeloma is also fueling the growth of the global retinal vein occlusion market.

According to the Centers for Disease Control and Prevention, in 2014, around 47,135 people were diagnosed with leukemia and out of which 23,564 people died from the disease. According to the American Cancer Society, around 4% of all cancers in the United States is lymphoma, additionally, it is estimated that in 2018, about 74,680 people including both adults and children will be diagnosed with lymphoma and around 19,910 people will die from this. According to the American Cancer Society, the risk of acquiring multiple myeloma in the United States is 1 in 143 that is 0.7%, additionally, it is estimated that in 2018, around 30,770 new cases are likely to be diagnosed and the estimated death toll would be around 12,770.

The global retinal vein occlusion market is expected to grow at a CAGR of 11.2% during the forecast period 2017-2023.

Taste the market data and market information presented through more than 150 market data tables and figures spread over 206 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “retinal vein occlusion market research report–Global forecast till 2023.”


Major Players in the Retinal Vein Occlusion Market
Some of the key players in this market are Allergan, Bayer, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Ellex Medical Lasers, GlaxoSmithKline Plc, IRIDEX Corporation, Novartis, Quantel Medical Inc, Topcon Medical Systems, Inc., ZEISS, Lumenis, Sanofi Aventis, Valeant Pharmaceuticals, Alimera Sciences, Fovea Pharmaceuticals SA, Icon Biosciences, Suzuken Co.Ltd, Genentech, Inc.,  Ranbaxy Pharmaceuticals, Johnson & Johnson Services, Inc, Teva Pharmaceutical, Pfizer Inc., Astrazeneca, Aerpio Therapeutics Inc, Annexin Pharmaceuticals AB  and others.
The global retinal vein occlusion market consists of four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa.

The Americas dominate the global retinal vein occlusion market owing to the increasing prevalence of eye diseases. Additionally, high healthcare spending, well-developed technology, and increasing geriatric population will fuel the growth of the market.  

The Americas market for retinal vein occlusion is divided into North America and South America. North America holds the major share in the market whereas, South America is showing the fastest growth owing to the presence of a huge opportunity for the development of the market in the region.

The Europe retinal vein occlusion market comprises of Eastern Europe and Western Europe. Western Europe comprises of countries such as Germany, the U.K, France, Italy, and Spain. Europe accounts for the second largest market for the global retinal vein occlusion owing to increasing support from the government, the presence of huge geriatric population, and high healthcare spending. Also, many European countries are trying to encourage the manufacturers for research & development for the introduction of advanced devices. In addition to this, increasing awareness and development in the healthcare infrastructure has provided a push to the growth of the market.

Asia Pacific is the fastest growing market for the global retinal vascular or vein occlusion. Presence of huge patient population, rapid development in technology and presence of a huge opportunity for the development of the market drives the growth of Asia Pacific retinal vascular or vein occlusion market. Also, the government of this region is looking forward to avail better treatment options from developed nations in order to improve the quality of life of their citizens. Additionally, growing geriatric population is also fueling the growth of the market in this region.

On the other hand, the Middle East & Africa holds the least share but will be a fastest growing region in the forecast period. However, due to the presence of poor and slow developing countries, especially, in the African region, it may hold least market share.

Segmentation
The global retinal vein occlusion market is segmented on the basis of type, condition, diagnosis, treatment, and end user. On the basis of the type, it is segmented into branch retinal artery occlusion and central retinal vein occlusion. On the basis of the condition, it is segmented into non-ischemic and ischemic. Based on the diagnosis, it is segmented into optical coherence tomography (OCT), fundoscopic examination, fluorescein angiography, and others. On the basis of treatment, it is segmented into antivascular endothelial growth factor, corticosteroid drugs, laser retinal photocoagulation, and others. On the basis of the end users, it is segmented into hospitals and clinics, research & academics centers, and others.


Posted by at No comments:
Labels: ,

Tuesday, July 30, 2019

Ontogenetic Market Witness Rapid Increase in Consumption By 2023

Ontogenetic Market – Overview
Rising interest in the field of genetics is leading to a considerable awareness of the developmental history of an organism. Market reports associated with the healthcare industry have been presented by Market Research Future which makes reports on other industry verticals that aims to analyze the current market scenarios better.  The market is set to chart a growth trajectory with a 4.2% CAGR in the course of the forecast period.
The knowledge undiscovered from the study of ontogenetic processes has created an increased potential for its application in various fields of study. The rise in human and animal population has further enhanced the scope for the development of the market. The diversification of the expansion of neurodiagnostic services is further propelling the potential of growth of the ontogenetic market in the upcoming period.


Segmental Analysis
The segmentation of the ontogenetic market is carried out on the basis of application, devices, end-user and region. Based on devices, the ontogenetic market is segmented into magnetoencephalography, electroencephalography, and others. The application basis of segmenting the ontogenetic market comprises of developmental psychology, developmental biology, developmental psychobiology, developmental cognitive neuroscience, and others. On the basis of the end user, the ontogenetic market is segmented into academic institutes, research laboratories, and others. Moreover, the research laboratories are segmented into independent or private research laboratories, government research laboratories, and others. The regions included in the ontogenetic market are the Americas, Europe, Asia Pacific, Africa, and the Middle East.

Detailed Regional Analysis
The regional analysis of the ontogenetic market consists of regions such as the Americas, Asia Pacific, Europe, Africa, and the Middle East. The Americas is observed to be dominating the ontogenetic market globally due to a huge amount of money directed towards research and development and clinical trials. The North American region is the principal regional market, while the South America region‘s ontogenetic market is also mounting at a noteworthy rate. The U.S. is the maximum revenue generating nation within the region. The European region is the succeeding largest market and is anticipated to develop rapidly through the forecast period. The chief European countries such as France, Germany, and the U.K are motivating the market. The Eastern European nations are also contributing a major stake to this regional market’s expansion. The U.K is anticipated to develop at a strong CAGR in the European region. The Asia Pacific region is a rapidly mounting ontogenetic market due to the mounting funding for research and development and government initiatives to support research in this field. Japan and China are the major players in this region, while India is rising in this market. Due to the lack of developed infrastructure and low investment in research and development, the Middle East & African region is expected to witness sluggish growth.

Competitive Analysis
The development of a strong value chain is additionally motivating the development of the market. The vertical supplements and product tactics of the market are advancing the potential of the market players. The growth of the market is moving in a promising direction due to new product introductions or intensifying gross revenue of the players in the market. Increased conformity of market players to new customers and market trend inclinations are boosting the growth curve of the market and will persist in the forecast period. The tactical goals intended for the market are buoyed due to advantageous product differentiation carried out by market contestants. Substantial cuts in administrative costs are inducing further expansion of the market. The effective implementation of strategies is likely to stimulate the market in the impending years.

The principal competitors in the ontogenetic market are Ontogeny, Inc (U.S.), EMS Handels Gesellschaft GmbH (Austria), ANT Neuro (the Netherlands), Natus Medical Incorporated (U.S.), Symbiotic Devices (Australia), and others.

Table Of Content
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
...Continued


Posted by at No comments:
Labels: ,

Thursday, July 25, 2019

Chronic Granulomatous Disease Market Report to Share Estimated Growth Rate By 2023

Chronic Granulomatous Disease Market Highlights
Chronic granulomatous disease (CGD) is a rare inherited immune deficiency caused due to a random mutation in the DNA. People affected with this disease have weakened immune systems which do not function properly. CGD is of two types, namely, X-linked CGD and autosomal recessive type. According to The Chronic Granulomatous Disorder Society, about 60% of people with CGD have X-linked CGD. People with CGD generally have bacterial infections including Salmonella, Klebsiella, Actinomyces, Streptococcus, Nocardia, and Serratia among others. Moreover, fungal infections such as Aspergillus fumigatus and Aspergillus nidulans are also common. The rising prevalence of rare diseases, growing expenditure on healthcare sector in the developed economies, and increasing research and development activities are expected to drive the growth of the market over the forecast period. On the other hand, the expensive diagnostic tests and treatment coupled with lack of awareness about the disease in the developing and underdeveloped economies may hamper the market growth over the assessment period.

The global chronic granulomatous disease market is currently dominated by many market players. The prominent players in the market are engaged in frequent new product launches and strategic collaborations to strengthen its market position. Currently, Actimmune (Interferon gamma-1b) manufactured by InterMune, Inc. is the approved by the US Food and Drug Administration (FDA) for treatment of chronic granulomatous disease.


Chronic Granulomatous Disease Market Regional Analysis
The market in the Americas is expected to dominate the global chronic granulomatous disease market during the forecast period owing to the growing prevalence of rare diseases, increasing research and development, and presence of well-developed healthcare sector. Europe is anticipated to hold the second largest position in the global chronic granulomatous disease market. The market growth in this region is attributed to the rising prevalence of rare diseases and increasing research and development activities. Asia-Pacific is expected to be the fastest growing market owing to the developing healthcare infrastructure, increasing awareness about rare genetic diseases, and increasing government funding for the healthcare sector. Furthermore, the Middle East and Africa region is expected to hold the least share in the global market owing to the slowly developing healthcare sector especially in the African region.

Chronic Granulomatous Disease Market Segmentation
The global chronic granulomatous disease market has been segmented into type, diagnosis, treatment, and end user.

The market, on the basis of type, is segmented into X-linked chronic granulomatous disease and autosomal recessive chronic granulomatous disease.

The market, by diagnosis, has been segmented into neutrophil function tests, genetic testing, prenatal testing, and others.

The market, by treatment, has been segmented into infection management, interferon-gamma, stem cell transplantation, and others. The infection management segment has been further segmented into trimethoprim, sulfamethoxazole, itraconazole, and others.

On the basis of end-user, the market has been segmented into hospitals, clinical laboratories, and others.

Chronic Granulomatous Disease Market Key Players
Some of the prominent players in the global chronic granulomatous disease market are Pfizer, Inc., InterMune, Inc., Novartis AG, Lonza Group, GlaxoSmithKline Plc, Eli Lilly and Company, Janssen Pharmaceuticals, Merck KGaA, Osiris Therapeutics, Inc, JCR Pharmaceuticals Co., Ltd., Maxcyte Inc., and Horizon Pharma Plc.

Table Of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
...Continued

Access Report @ https://www.marketresearchfuture.com/reports/chronic-granulomatous-disease-market-6447

Posted by at No comments:
Labels: ,

Wednesday, July 24, 2019

Membranous Nephropathy Market to Grow at a Stellar Pace Reflecting a 3.5% CAGR by 2023

Market Research Future (MRFR) announces the publication of its research report – Global Membranous Nephropathy Market 2017–2023

Market Highlights
Membranous nephropathy is a kidney disorder. It is an autoimmune disorder which can occur by itself or in conjunction with several other diseases. Membranous nephropathy is one of the most common causes of nephrotic syndrome. Membranous nephropathy can be caused due to various factors such as any autoimmune disease, use of certain medications such as nonsteroidal anti-inflammatory drugs, and exposure to certain infection such as hepatitis B, hepatitis C, and syphilis.

According to the World Health Organization (WHO), globally around 71 million people have the hepatitis C infection. This alarming rate of hepatitis C infections globally is likely to increase the market for membranous nephropathy. 


The Global Membranous Nephropathy Market is expected to grow at a CAGR of 3.5% during the forecast period.

Regional Analysis
The Americas dominates the global membranous nephropathy market owing to the rising aging population and increasing rate of kidney disorders. Additionally, rising patient population rates along with increasing healthcare expenditure are likely to enhance the growth of membranous nephropathy in the North American region. Similarly, according to the National Kidney Foundation, in 2015 the U.S. is expected to spend around USD 48 million for the treatment of chronic kidney diseases.

Europe accounts for the second largest market due to increasing aging mass and increasing obesity rates. Additionally, improving government support and increasing healthcare infrastructure along with rising demand for technologically advanced treatment is driving the growth of the membranous nephropathy market in Europe. For instance, Eurostat estimated that over 19.2% of the population in Europe was aged 65 and above. Additionally, according to NHS, around 215,000 people have hepatitis C in the U.K. These rising rates in infection affected population is likely to drive the growth of the membranous nephropathy market.

Asia Pacific is the fastest growing market for membranous nephropathy whose growth is attributed to the rising population, which in turn increases the overall patient population and rising population affected by genetic disorders. Additionally, increasing healthcare expenditure and demand for new and innovative treatment options along with the rise in the standard of living are likely to drive the growth of the market. India and China are the foremost contributors to the market growth due to the growing demand for advanced treatments and rising rapid development of healthcare infrastructure in these regions.

On the other hand, the Middle East and Africa is expected to witness a limited growth due to limited access to healthcare and lack of awareness among individuals. In the Middle East, the growth of the market is driven by the increasing introduction of new and innovative products for diagnostic and treatment of various chronic diseases.

Segmentation
The global membranous nephropathy market is segmented on the basis of type, treatment, diagnosis, and end-user.
On the basis of type, the market is segmented into primary and secondary.
On the basis of treatment, the market is segmented into conservative therapy, non-immunosuppressive therapy, and immunosuppressive therapy.
On the basis of diagnosis, the market is segmented into urine test (urinalysis), blood test, glomerular filtration rate test, antinuclear antibody test, kidney ultrasound or Computed Tomography (CT), kidney biopsy, anti-PLA2R antibody test, and others.
On the basis of end-user, the market is segmented into research centers, hospitals, and specialty centers.

Key Players
Some of the key players in the Membranous Nephropathy market are Abbvie, Inc., Allergan Plc., Amgen Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd, and FibroGen, Pfizer Inc., among others.

Table Of Content
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
...Continued


Posted by at No comments:
Labels: ,

Tuesday, July 23, 2019

Traumatic Brain Injuries (TBI) Treatment Market Expanding at a Steady CAGR of 5.1% through 2023

Traumatic Brain Injuries Treatment Market Highlights:
Traumatic brain injury (TBI) occurs from a violent blow or head injury that disturb the normal functioning of the brain. Every year TBI contributes to a substantial number of death and permanent disability. Elder age population holds the largest share of global traumatic brain injuries treatment market due to increasing incidence of road accident and high rate of hospitalization and is expected to grow staidly during the forecast period. Whereas on the basis of treatment, medication (drug) segment holds the highest share of this market. Increasing incidences of road traffic injury and the government initiatives to fund for traumatic brain injuries project will boost the traumatic brain injuries treatment market during assessment period.

However, high cost of treatment and devices may hamper the growth of global traumatic brain injuries treatment market during the forecast period.

The global traumatic brain injuries treatment market is dominated by many market players. The key players in the market are engaged in new launches of drug and devices so as to maintain the strategic collaborations to hold its market position. Recently the US FDA has approved the blood test to diagnose the traumatic brain injury.


Traumatic Brain Injuries Treatment Market  Regional Analysis:
The market in the Americas is expected to dominate the global traumatic brain injuries treatment market during the forecast period owing to the increasing incidences of road traffic injuries and increasing hospitalization of geriatric population due to TBI. Additionally, the growing incidences of road traffic collision associated with the aging population are anticipated to boost the growth of the market in this region. Whereas North America holds the highest share of global traumatic brain injury treatment due to increasing number of TBI patients and increasing investment by government in research and development activity on diagnosis management. The European market is expected to be the second-largest due to government funding and support of the healthcare sector coupled with the growing incidence of elderly patients, increasing incidences of road traffic collision and funding by the government for traumatic brain injury project. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the assessment period owing to growing number of neurological centers and increasing incidences of road accident. The market in the Middle East & Africa is likely to account for the smallest share of this market. The market growth in this region can be attributed to increasing healthcare expenditure and developing healthcare infrastructure.

Traumatic Brain Injuries Treatment Market  Segmentation:
Global traumatic brain injuries treatment market is further segmented into treatment types and end-users.
Based on treatment types the market is segmented into immediate emergency care, medications, surgery. On basis of medication global traumatic brain injuries treatment market is further sub-segmented into diuretics, anti-seizure drugs, coma-inducing drugs, anti-anxiety agent, anti-depressants, anti-psychotics, analgesic, anti-convulsant and anti-coagulants.

Based on surgery, TBI market is further sub-segmented into removing clotted blood (hematomas), repairing skull fractures, bleeding in the brain, opening a window in the skull, rehabilitation.
On basis of end-users global TBI market is further segmented into hospitals, neurologist, rehabilitative center treatment, independent pharmacies and others.

Traumatic Brain Injuries Treatment Market  Key Players:
Some of the key players in the Global Traumatic brain injuries treatment market  are Neuren Pharmaceuticals Ltd., Oxygen Biotherapeutics Inc, Ischemic,  Grace Laboratories LLC. Cognosci, Medicortex, Amarantus BioScience Holdings, Aldagen, TEVA Pharmaceutical Industries Ltd., NeuroScience Pharmaceuticals, Targacept, BioDirection, Inc., QuesGen Systems, Inc., BrainScope Company, Inc., Oculogica, BrainScope Company, Inc, Vasopharm GmbH, Silver Creek Pharmaceuticals Inc, Stemedica Cell Technologies Inc, Neural Analytics Inc, Banayan Biomarkers Inc, Zimmer Biomet.

Table Of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction 
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations 
Chapter 3. Research Methodology 
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation 
Chapter 4. Market Dynamics 
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment 
Chapter 5. Market Factor Analysis
...Continued


Posted by at No comments:
Labels: ,

Pharmacy Repackaging Systems Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast to 2023

Pharmacy Repackaging Systems Market Highlights
It is estimated that the global pharmacy repackaging systems market is expected to register a CAGR ~ 7% during the forecast period of 2018–2023.

Usually FDA, regards the repackaging as a process of transferring a finished drug product into another container to repackage without further manipulation of the drug. The global pharmacy repackaging systems market is expected to witness tremendous growth owing to the stringent regulations by various government. Other key factors such as the rise in number of outpatient visits encourages pharmacists and hospitals to incorporate automated systems in order to improve their prescription-handling capacity are contributing towards the growth of the market. Also, the high efficiency rate of the pharmacy repackaging systems is estimated to boost the growth of the market. However, factors such as lack of trained medical professionals is expected to curb the growth of the market during the forecast period.


On the regional basis, the pharmacy repackaging systems market in the Americas is predicted to dominate the market during the forecast period. The North American region holds substantial share in the global market. This owes to the increase in awareness of automated systems in developed economies, reduction in dispensing errors, increased patient compliance are influencing the growth of pharmacy repackaging systems market in this region.
For instance, in May 2016, as per the Johns Hopkins University, nearly 250,000 people in the U.S die due to medical errors. Health care providers and pharmacists are focusing on improving outpatient medication to improve operational efficiency, in terms of staff productivity and patient safety.

The major players in this market are involved in new product launches, strategic partnerships and collaborations to increase their product portfolio. Also, numerous major players are based in the US, owing to which the US has become a center for innovation in the pharmacy repackaging systems market.

The global pharmacy repackaging systems market is segmented on the basis of product type, dosage type, and end user.
Some of the key players in the global intraocular lens market are Omnicell, Inc., Becton Dickinson & Company (CareFusion Corporation), Kirby Lester, Swisslog Holding Ltd., Yuyama Co., Ltd., TCGRx, Takazono Corporation, Parata Systems, Pearson Medical Technologies, ARxIUM, Medical Packaging Inc., Pearson Medical Technologies, Proficient Rx, among others.

Table Of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Overview
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
5.2 Value Chain Analysis
Chapter 6. Global Pharmacy Repackaging Systems Market, By Product Type
...Continued


Posted by at No comments:
Labels: ,

Monday, July 22, 2019

Multiplex Assays Market to Witness Increasing Revenue Growth By 2023

Market Research Future Published a Half-Cooked Research Report on Global Multiplex Assays Market Research Report.

Multiplex Assays Market Insight
Multiplex Assays are used to detect multiple analytes in a single run of the assay. These are widely used in genomics to quantify mRNAs, DNAs, and proteins to assess the effect of DNA mutation on various biomolecules in the given sample. With multiplex assays, scientists can gain more information about a single protein or series of proteins within a single well or reaction of an experiment. This not only helps the scientists to conserve time and cost but also save on their sample quantity. Researchers are using multiplex assays to detect cellular regulatory events occurring in chronic diseases such as cancer. The multiplex assay market is dominated by North America due to increase in R&D activities and rising R&D expenditure in this region. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), the U.S. carries out nearly half of the world's pharmaceutical Research and Development (R&D) and possesses the intellectual property rights on most of the newly developed medicines, thus driving the market growth in this region.


Multiplex Assays Market Segmentation
The global multiplex assays market is segmented on the basis of product and service, type, technology, application, and end-user. The multiplex assays market, by product and service, is sub-segmented into consumables, instruments, software and services, and others. On the basis of type, the market is categorized into protein multiplex assays, nucleic acid multiplex assays, cell-based multiplex assays, and others. Protein multiplex assays are further sub-segmented into planar protein assays, bead-based protein assays, and others. Nucleic acid multiplex assays are further sub-segmented into planar nucleic acid assays, bead-based nucleic acid assays, and others. The technology segment includes flow cytometry, fluorescence detection, luminescence, real-time multiplex PCR, and others. On the basis of application, the market is categorized into research and development and clinical diagnostics. The research and development segment includes drug discovery and development and biomarker discovery and validation. The clinical diagnostics segment includes infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, nervous system disorders, metabolism and endocrinology disorders, and others. On the basis of end-user, the market is segmented into pharmaceutical and biotechnology companies, hospitals and research institutes, reference laboratories, and others.

Multiplex Assays Market Key players
Some of the key players for the global multiplex assays market are Luminex, Thermo Fisher Scientific, Illumina, Bio-Rad Laboratories, Qiagen, Abcam, Becton Dickinson and Company, Merck, Agilent Technologies, Meso Scale Diagnostics, Randox Laboratories, Quanterix, Bio-Techne, Olink, Seegene, and others.

Table Of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
...Continued

Access Report @ https://www.marketresearchfuture.com/reports/multiplex-assays-market-6135

Posted by at No comments:
Labels: ,

Rapid Sterility Testing Market to expand at a value CAGR of 13.4% During 2017 - 2023

Rapid Sterility Testing Market Highlights
The global rapid sterility testing is anticipated to have held a market value of USD 158 million in the year 2017 and is expected to grow at a CAGR of 13.4% during the forecast period. Rapid sterility testing used to detect microbial contamination in given biologic sample. It is an alternative method for sterility testing.
Increasing R&D expense and new product launches are expected to drive the growth of the market. According to the Center for Drug Evaluation and Research, in 2017, about 46 novel drug approvals were the 22 novel drug approval in 2016. On the other hand, the availability of the alternative traditional method can restrain the market growth over the assessment period.


Rapid Sterility Testing Market Regional Analysis
Geographically, the Americas is expected to dominate the global market owing to the presence of well-established players and growth in pharmaceutical and medical device companies. Europe is expected to hold the second largest position in the global market. Asia-Pacific is expected to be the fastest growing market owing to the increasing adoption of the technologies. Furthermore, the Middle Eastern and African region is expected to account for the least market share in the global market.

Rapid Sterility Testing Market Segmentation
The global rapid sterility testing market has been segmented into product, technology, and application.
Based on product, the market is segmented into kits & reagents, instruments, and services. The kits & reagents segment is expected to account for the largest share and fastest growing segment of the global market in 2017.
Based on technology, the market is segmented into membrane filtration, ATP bioluminescence, and others. The ATP bioluminescence segment is expected to account for the largest share segment of the global market in 2017.
Based on application, has been segmented into pharmaceutical and biological manufacturing, medical device manufacturing, other end users.

Rapid Sterility Testing Market Key Players
Some of the prominent players in the global rapid sterility testing market are Charles River Laboratories, Inc. (US), Gibraltar Laboratories (US), Merck KGaA (Germany), Rapid Micro Biosystems, Inc. (US), bioMérieux (France), Eurofins Scientific (Luxembourg), Becton, Dickinson and Company (US), FOCUS Laboratories (US), Sartorius AG (Germany), and Thermo Fisher Scientific (US).


Posted by at No comments:
Labels: ,

Sunday, July 21, 2019

Atorvastatin API Market Going to Reach USD 4,25,804.16 thousand by the end of 2023

Atorvastatin API Market Highlights
The Global Atorvastatin API Market is estimated to be valued at USD 4,25,804.16 thousand by 2023 and is expected to register a CAGR of 3.34% during the forecast period.

The hypercholesterolemia segment is expected to lead the market and register a substantial CAGR to reach USD 2,10,753.23 thousand by the end of 2023. High prevalence of hypercholesterolemia is expected to drive the market growth. Additionally, the segment is projected to exhibit the highest CAGR of 4.09% from 2018 to 2023.

North America accounted for the largest market share of 40.64% in 2017, and the regional market is projected to register a CAGR of 3.10% during the forecast period. Asia-Pacific is expected to register the fastest CAGR. The Chinese market is projected to exhibit the highest growth rate of 5.86% during the forecast period from 2018 to 2023.


Atorvastatin API Market Segment Analysis
The hypercholesterolemia segment is expected to lead the market and register a substantial CAGR to reach USD 2,10,753.23 thousandby the end of 2023. High prevalence of hypercholesterolemia is expected to drive the market growth. Additionally, the segment is projected to exhibit the highest CAGR of 4.09% from 2018 to 2023.

Atorvastatin API Market Players
Market Research Future (MRFR) recognizes Teva Pharmaceutical Industries Ltd (Israel), Jubilant Life Sciences Ltd (India), Dr. Reddy’s Laboratories Ltd (India), Sun Pharmaceutical Industries Ltd (India), Ind-Swift Labs Ltd (India), Morepen Laboratories Ltd (India), Zhejiang Hisun Pharmaceutical Co Ltd (China), Anuh Pharma Ltd (India), Centrient Pharmaceuticals (The Netherlands) and Cadila Pharmaceuticals (India) as the key players in the global atorvastatin API market.

Atorvastatin API Market Regional Analysis
North America accounted for the largest market share of 40.64% in 2017, and the regional market is projected to register a CAGR of 3.10% during the forecast period. Asia-Pacific is expected to register the fastest CAGR. The Chinese market is projected to exhibit the highest growth rate of 5.86% during the forecast period from 2018 to 2023. 

The European market is estimated to exceed USD 1,31,094.04 thousand by 2023. High prevalence of hypercholesterolemia and mixed dyslipidemia are driving the growth of the Atorvastatin API market in the region. France is the major contributor to the growth of the regional market, followed by the UK.

Key Findings of the Atorvastatin API Market Study
  • The Global Atorvastatin API Market is projected to reach over USD 4,25,804.16 thousand by 2023 at 34% CAGR during the review period of 2018 to 2023.
  • North America accounted for the largest market share with the US being the major contributor to the growth of the market.
  • The hypercholesterolemia segment is projected to register the highest CAGR of 4.09% during the forecast period owing to the rising rate of hypercholesterolemia cases.
  • Key manufacturers are adopting geographic expansions, corporate acquisitions and product launches as growth strategies.

Posted by at No comments:
Labels: ,

Thursday, July 18, 2019

Doxorubicin Market Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast By 2023

Doxorubicin Market Highlights
Doxorubicin is a type of chemotherapy medicine called an anthracycline. It is used to reduce or diminish the growth of cancer cells by blocking an enzyme called topo isomerase. Factors that are propelling the growth of the doxorubicin market are surge in geriatric population, rising prevalence of different types of cancer, increasing awareness for cancer treatment. According to the International Federation of Pharmaceutical Manufacturers & Associations, global pharmaceutical industry has spent more than USD 149.8 billion on pharmaceutical Research and development activities.

The various side effects, cost containment policies by various governments, stringent regulatory environment for product approval, are likely to hinder market growth during the forecast period.


Doxorubicin Market Regional Analysis
The American market is expected to dominate the global doxorubicin market during the forecast period due to the presence of major manufacturers, increase in number of cancer cases, awareness for the treatment of cancer, and favorable reimbursement and regulatory authorities. The European market is expected to be the second-largest due to growing pool of cancer patients and rising healthcare expenditure. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to the increasing geriatric population in countries such as India and China, increasing awareness programs for the treatment of cancer, government initiatives and investment for the development of healthcare sector and increasing number manufacturers finding opportunities in developing countries. The market in the Middle East & Africa is likely to account for the smallest share of the global doxorubicin market.

Doxorubicin Market Segmentation

The global doxorubicin market has been segmented on the basis of application, and distribution channel.
The application segment is divided into liver cancer, gastric cancer, breast cancer, bone sarcoma, prostate cancer, stomach cancer, ovarian cancer, leukemia and others.
The market, by distribution channel, has been segmented into hospital pharmacy, retail pharmacy and others.

Doxorubicin Market Key Players
Some of the key players in the global Doxorubicin market are Doxorubicin market are Pfizer, Inc, Sun Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Accord Healthcare, Novartis AG, Sandoz, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceuticals, GLENMARK PHARMACEUTICALS LTD. and various others

Table Of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
...Continued


Posted by at No comments:
Labels: ,

Lupus Market Research, Report, In-depth Insight, Industry Forecast to 2023

Lupus Market Overview:
Lupus is a chronic autoimmune disease which occurs when the immune system attacks the healthy cells and tissues of the body, thereby causing inflammation, pain, swelling, and damage throughout the body. Many people have an inherit tendency towards developing or attaining lupus, which can be triggered due to certain drugs, infections, or even sunlight. The prevalence of this condition has prompted Market Research Future (MRFR) to take notice and study the global market of the same. As of 2017, the market valuation of Lupus stood at USD 1.48 billion. However, as per the latest studies, the global lupus market is projected to grow significantly during the forecast period with a CAGR of 11.2%.

Various factors such as the growing prevalence of lupus diseases, increasing R&D activities, and continuing medical advancements for the treatment of systemic lupus erythematosus are all identified as key factors driving the growth of the market. Also, the market involves a number of noteworthy companies that are involved in the development of new products and product launches. However, irrespective of the market drivers, constraints such as strict government regulation and rising prices of lupus drugs can severely hamper its market growth during the review period.


Lupus Market Segmentation
The lupus market segmentation is done on the basis of treatment, end-user, and types.
By treatment, the market includes antimalarial drugs, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), biologics, immunosuppressants, and others.
By end-user, the market divides into diagnostic laboratories, hospitals and clinics, and others.

Lastly, by type, the market comprises cutaneous lupus erythematosus, systemic lupus erythematosus, neonatal lupus, and drug-induced lupus erythematosus. The lupus erythematosus market segment is projected to hold the largest market percentage due to the increasing prevalence of such diseases and the increasing drug development over the years.

Lupus Market Regional Analysis

The global lupus market is geographically segmented into the following regions: Americas, Asia Pacific, Europe, and the Middle East & Africa.

The Americas is anticipated to be the most dominant regional market due to a number of factors. This includes the growing prevalence of lupus diseases, rising demand for better treatment options, favorable government initiatives, and the availability of reimbursement. In addition to these, the established healthcare infrastructure facility coupled with the accessibility to biologics are also expected to propel the market growth of this region.

The European market is believed to hold the second-largest market position following the Americas. The growth of the market herein is attributed to the expanding R&D activities and widespread prevalence of lupus diseases.

The Asia-Pacific region is expected to be the fastest-growing regional market. This can be attributed to the growing healthcare sector, the rising incidences of lupus diseases, and increasing regional expansion by prominent market players.

The Middle East & Africa region holds the least market share among all the mentioned regions.

Lupus Market Competitive Landscape
The global lupus market holds a number of noteworthy players, including Merck KGaA, Cadila Healthcare, Mylan N.V., F. Hoffmann-La Roche AG, Aurinia Pharmaceuticals, Inc., GlaxoSmithKline PLC, Eli Lily and Company, Pfizer, Inc., Bristol-Myers Squibb Company, Lycera Corporation, and Sanofi.

Dec 11th, 2018, Neovacs, a pioneer in the field of active immune therapy for treating autoimmune diseases, announced the continuation of its partnership with Centurion Pharma in Lupus (SLE). This is based on the study results of the Phase IIb trial with IFNalpha Kinoid.

Table Of Contents
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
...Continued

Browse Complete Report Details @ https://www.marketresearchfuture.com/reports/lupus-market-6636  

Posted by at No comments:
Labels: ,
Subscribe to: Posts (Atom)